Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights

References

• Agniswamy, J., Shen, C. H., Aniana, A., Sayer, J. M., Louis, J. M., & Weber, I. T. (2012). HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry, 51, 2819–2828.
   PubMed Web of Science ®Google Scholar
• Agniswamy, J., Shen, C. H., Wang, Y. F., Ghosh, A. K., Rao, K. V., Xu, C. X., … Weber, I. T. (2013). Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1ʹ-pyrrolidinone or P2-tris-tetrahydrofuran. Journal of Medicinal Chemistry, 56, 4017–4027.
   PubMed Web of Science ®Google Scholar
• Ahmed, S. M., Kruger, H. G., Govender, T., Maguire, G. E. M., Sayed, Y., Ibrahim, M. A. A., … Soliman, M. E. S. (2013). Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR. Chemical Biology & Drug Design, 81, 208–218.
   PubMed Web of Science ®Google Scholar
• Ahmed, S. M., Maguire, G. E. M., Kruger, H. G., & Govender, T. (2014). The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints. Chemical Biology & Drug Design, 83, 472–481.
   PubMed Web of Science ®Google Scholar
• Bauer-Mehren, A. (2013) Integration of genomic information with biological networks using Cytoscape. Methods in Molecular Biology (Clifton, N.J.), 1021, 37–61.
   PubMedGoogle Scholar
• Bennett, D. E., Camacho, R. J., Otelea, D., Kuritzkes, D. R., Fleury, H., Kiuchi, M., … Shafer, R. W. (2009). Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS One, 4, e4724.
   PubMed Web of Science ®Google Scholar
• Bhakat, S., Martin, A. J. M., & Soliman, M. E. S. (2014). An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine. Molecular Biosystems, 10, 2215–2228.
   PubMed Web of Science ®Google Scholar
• Brik, A. & Wong, C. H. (2003). HIV-1 protease: Mechanism and drug discovery. Organic & Biomolecular Chemistry, 1, 5–14.
   PubMed Web of Science ®Google Scholar
• Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., … Woods, R. J. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26, 1668–1688.
   PubMed Web of Science ®Google Scholar
• Doncheva, N. T., Klein, K., Domingues, F. S., & Albrecht, M. (2011). Analyzing and visualizing residue networks of protein structures. Trends in Biochemical Sciences, 36, 179–182.
   PubMed Web of Science ®Google Scholar
• Doss, C. G. P., Rajith, B., Chakraboty, C., Balaji, V., Magesh, R., Gowthami, B., … Das, M. (2014). In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach. Molecular Biosystems, 10, 421–436.
   PubMed Web of Science ®Google Scholar
• Flexner, C. (2007). HIV drug development: The next 25 years. Nature Reviews Drug Discovery, 6, 959–966.
   PubMed Web of Science ®Google Scholar
• Foulkes-Murzycki, J. E., Rosi, C., Yilmaz, N. K., Shafer, R. W., & Schiffer, C. A. (2013). Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chemical Biology, 8, 513–518.
   PubMed Web of Science ®Google Scholar
• Freedberg, D. I., Ishima, R., Jacob, J., Wang, Y.-X., Kustanovich, I., Louis, J. M., & Torchia, D. A. (2002). Rapid structural fluctuations of the free HIV protease flaps in solution: Relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Science, 11, 221–232.
   PubMed Web of Science ®Google Scholar
• Heal, J. W., Jimenez-Roldan, J. E., Wells, S. A., Freedman, R. B., & Romer, R. A. (2012). Inhibition of HIV-1 protease: The rigidity perspective. Bioinformatics, 28, 350–357.
   PubMed Web of Science ®Google Scholar
• Heaslet, H., Rosenfeld, R., Giffin, M., Lin, Y.-C., Tam, K., Torbett, B. E., … Stout, C. D. (2007). Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallographica Section D-Biological Crystallography, 63, 866–875.
   PubMed Web of Science ®Google Scholar
• Hornak, V., Okur, A., Rizzo, R. C., & Simmerling, C. (2006a). HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proceedings of the National Academy of Sciences United States of America, 103, 915–920.
   PubMed Web of Science ®Google Scholar
• Hornak, V., Okur, A., Rizzo, R. C., & Simmerling, C. L. (2006b) Flap structure and dynamics in HIV-1 protease simulations. Abstracts of Papers of the American Chemical Society, 231, 915–920.
   Google Scholar
• Hornak, V., Okur, A., Rizzo, R. C., & Simmerling, C. (2006c). HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state. Journal of the American Chemical Society, 128, 2812–2813.
   PubMed Web of Science ®Google Scholar
• Hornak, V., & Simmerling, C. (2007). Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discovery Today, 12, 132–138.
   PubMed Web of Science ®Google Scholar
• Kamaraj, B., & Purohit, R. (2013). In silico screening and molecular dynamics simulation of disease-associated nsSNP in TYRP1 gene and its structural consequences in OCA3. Biomed Research International, 2012, 1–13.
   Web of Science ®Google Scholar
• Karthik, S., & Senapati, S. (2011). Dynamic flaps in HIV-1 protease adopt unique ordering at different stages in the catalytic cycle. Proteins-Structure Function and Bioinformatics, 79, 1830–1840.
   PubMed Web of Science ®Google Scholar
• Karubiu, W., Bhakat, S., & Soliman, M. S. (2014). Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: Insight from molecular dynamics simulation. Protein Journal, 5, 1–15.
   Google Scholar
• Leonis, G., Steinbrecher, T., & Papadopoulos, M. G. (2013). A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation 150V: A systematic MM-PBSA and thermodynamic integration study. Journal of Chemical Information and Modeling, 53, 2141–2153.
   PubMed Web of Science ®Google Scholar
• Liu, F. L., Kovalevsky, A. Y., Tie, Y. F., Ghosh, A. K., Harrison, R. W., & Weber, I. T. (2008). Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. Journal of Molecular Biology, 381, 102–115.
   PubMed Web of Science ®Google Scholar
• Makatini, M., Petzold, K., Alves, C., Arvidsson, P., Honarparvar, B., Govender, P., … Soliman, M. (2013). Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane. Journal of Enzyme Inhibition and Medicinal Chemistry, 28, 78–88.
   PubMed Web of Science ®Google Scholar
• Mehellou, Y. & De Clercq, E. (2010). Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? Journal of Medicinal Chemistry, 53, 521–538.
   PubMed Web of Science ®Google Scholar
• Mittal, S., Bandaranayake, R. M., King, N. M., Prabu-Jeyabalan, M., Nalam, M. N. L., Nalivaika, E. A., … Schiffer, C. A. (2013). Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50. Journal of Virology, 87, 4176–4184.
   PubMed Web of Science ®Google Scholar
• Mittal, S., Cai, Y., Nalam, M. N. L., Bolon, D. N. A., & Schiffer, C. A. (2012). Hydrophobic core flexibility modulates enzyme activity in HIV-1 Protease. Journal of the American Chemical Society, 134, 4163–4168.
   PubMed Web of Science ®Google Scholar
• Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H. M., … Kempf, D. J. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine, 2, 760–766.
   PubMed Web of Science ®Google Scholar
• Muzammil, S., Ross, P., & Freire, E. (2003). A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry, 42, 631–638.
   PubMed Web of Science ®Google Scholar
• Naicker, P., Achilonu, I., Fanucchi, S., Fernandes, M., Ibrahim, M. A. A., Dirr, H. W., … Sayed, Y. (2013). Structural insights into the South African HIV-1 subtype C protease: Impact of hinge region dynamics and flap flexibility in drug resistance. Journal of Biomolecular Structure and Dynamics, 31, 1370–1380.
   PubMed Web of Science ®Google Scholar
• Perryman, A. L., Lin, J. H., & McCammon, J. A. (2004). HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs (vol 13, pg 1108, 2004). Protein Science, 13, 1434–1434.
   Web of Science ®Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF chimera – A visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25, 1605–1612.
   PubMed Web of Science ®Google Scholar
• Piana, S., Carloni, P., & Rothlisberger, U. (2002). Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Science, 11, 2393–2402.
   PubMed Web of Science ®Google Scholar
• Rhee, S. Y., Taylor, J., Fessel, W. J., Kaufman, D., Towner, W., Troia, P., … Shafer, R. W. (2010). HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrobial Agents and Chemotherapy, 54, 4253–4261.
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham III, T. E. (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9, 3084–3095.
   PubMed Web of Science ®Google Scholar
• Scott, W. R. P. & Schiffer, C. A. (2000). Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure, 8, 1259–1265.
   PubMed Web of Science ®Google Scholar
• Shenai, P. M. X. & Zhao, Z. (2012). Applications of Principal Component Analysis (PCA) in Materials Science. In P. Sanguansat (Ed.), Principal component analysis-engineering applications (pp. 1–40). InTech. ISBN: 978-953-51-0182-6. Retrieved from http://www.intechopen.com/books/principalcomponent-analysis-engineering-applications/applications-of-principal-component-analysis-pca-in-materialsscience
   Google Scholar
• Spinelli, S., Liu, Q. Z., Alzari, P. M., Hirel, P. H., & Poljak, R. J. (1991). The 3-dimensional structure of the aspartyl protease from the HIV-1 isolate bru. Biochimie, 73, 1391–1396.
   PubMed Web of Science ®Google Scholar
• Tie, Y. F., Boross, P. I., Wang, Y. F., Gaddis, L., Liu, F. L., Chen, X. F., … Weber, I. T. (2005). Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstrom resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS Journal, 272, 5265–5277.
   PubMed Web of Science ®Google Scholar
• von der Helm, K. (1996). Retroviral proteases: Structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. Biological Chemistry, 377, 765–774.
   PubMed Web of Science ®Google Scholar
• Walsh, I., Martin, A. J. M., Di Domenico, T., & Tosatto, S. C. E. (2012). ESpritz: Accurate and fast prediction of protein disorder. Bioinformatics, 28, 503–509.
   PubMed Web of Science ®Google Scholar
• Wlodawer, A. & Vondrasek, J. (1998). Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annual Review of Biophysics and Biomolecular Structure, 27, 249–284.
   PubMedGoogle Scholar
• Zhang, Y., Chang, Y.-C. E., Louis, J. M., Wang, Y.-F., Harrison, R. W., & Weber, I. T. (2014). Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps. ACS Chemical Biology, 9, 1351–1358.
   PubMed Web of Science ®Google Scholar
• Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., & Salzman, N. P. (1997). Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. Journal of Virology, 71, 6662–6670.
   PubMed Web of Science ®Google Scholar
• Zhu, Z. W., Schuster, D. I., & Tuckerman, M. E. (2003). Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease. Biochemistry, 42, 1326–1333.
   PubMed Web of Science ®Google Scholar